Kymera Therapeutics posts corporate deck outlining push to develop oral targeted protein degraders for immunology
Reuters2026/08/05 12:09- Kymera outlined a strategy to commercialize oral targeted protein degraders in immunology, aiming to match biologics-like activity with pill convenience.
- Lead asset KT-621, an oral STAT6 degrader, positioned for dupilumab-like efficacy across Type 2 inflammatory diseases; Phase 2b atopic dermatitis data due by year-end 2026.
- Phase 3 atopic dermatitis trials planned to start by mid-2027; Phase 2b asthma readout targeted for late 2027.
- Second wholly owned program KT-579, an IRF5 degrader, targets lupus and related autoimmune diseases; Phase 1 healthy-volunteer data expected in 4Q26.
- Partnered pipeline includes KT-485, an IRAK4 degrader with an IND targeted for 2027, alongside KT-200, a CDK2 degrader for solid tumors.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The first major "exam" after the Cook era! Morgan Stanley: Apple's (AAPL.US) autumn launch event is the most important in ten years; the first foldable iPhone may spark a new wave of growth
Morgan Stanley analysts stated that Apple's upcoming "Surprise and Shine" autumn product launch event on September 9 may become the company's most important product release in nearly a decade.
10-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - Germany vs Other Nations
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
